These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25753330)

  • 21. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Matsukuma S; Nakamura Y; Yoshihara M; Koizume S; Sekiguchi H; Saito H; Nakayama H; Kameda Y; Yokose T; Oguni S; Niki T; Miyagi Y
    Lab Invest; 2013 Oct; 93(10):1137-46. PubMed ID: 23938604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
    Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
    Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Yokose T; Kameda Y; Koizume S; Miyagi Y
    Lab Invest; 2012 Mar; 92(3):371-83. PubMed ID: 22157722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
    Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
    Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
    Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
    J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPARĪ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARĪ³/PTEN/Akt pathway.
    Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
    Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP
    Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.